COAPT Likely To Propel TMVR Opportunity

18 September 2018

The COAPT trial evaluates whether MitraClip improves outcomes vs. medical therapy alone in patients with functional MR

COAPT Likely To Propel TMVR Opportunity
There is tremendous interest among physicians and investors in the treatment of mitral regurgitation (MR) because it represents a much larger potential market opportunity compared to aortic stenosis. 
Based on (1) the public commentary from the COAPT co-principal investigators; (2) the favorable results from the COAPT roll-in procedures; and (3) the recent initiation of the COAPT continued access study (CAS), it is expected that the trial shows a benefit in favor of MitraClip on at least one of the two key hard endpoints (heart failure hospitalization and/or mortality). If this is the case, we would expect MitraClip to receive an indication for FMR in the US in 2019.

The results of COAPT will be presented at TCT (Transcatheter Cardiovascular Therapeutics) on Sept. 23, 10:20 am at the Main area.

Experts from Meditrial will attend this conference and we would welcome the opportunity to learn about your product. We will be happy to provide a free consultation regarding your clinical project.
Plan to meet with us! Contact us to schedule a time to meet up. 

Location: San Diego Convention Center
111 W Harbor Drive, San Diego, CA 92101

Website: TCT 2018 San Diego
« Go back